225780-77-8

Basic information

• Product Name: N-TERT-BUTOXYCARBONYL-AZIDO-D-ALANINE
• Synonyms: Boc-D-Dap(N3) CHA salt;N-TERT-BUTOXYCARBONYL-AZIDO-D-ALANINE;Boc-D-Aza-OH*CHA;3-Azido-N-[(1,1-dimethylethoxy)carbonyl]-D-alanine;3-Azido-N-Boc-D-alanine;Boc-D-Ala(N3)·CHA;Boc-D-Dap(N3)-OH·CHA;Nα-Boc-Nβ-Azido-D-2,3-diaminopropionic acid cyclohexylammonium salt≥ 99% (HPLC)
• CAS NO: 225780-77-8
• Molecular Formula: C₈H₁₄N₄O₄
• Molecular Weight: 230.22116
• Product Categories: amino acids
• Mol File: 225780-77-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-TERT-BUTOXYCARBONYL-AZIDO-D-ALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-TERT-BUTOXYCARBONYL-AZIDO-D-ALANINE(225780-77-8)
• EPA Substance Registry System: N-TERT-BUTOXYCARBONYL-AZIDO-D-ALANINE(225780-77-8)

Safety Data

• Hazardous Substances Data: 225780-77-8(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Upstream product

• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 
• 301671-17-0 methyl (R)-3-azido-2-[(tert-butyloxycarbonyl)amino]propionate 
• 98541-64-1 N-(tert-butyloxycarbonyl)-D-serine β-lactone 

Downstream Products

• 1389332-02-8 C₂₁H₂₉N₅O₇ 
• 1414915-98-2 (S)-dimethyl-2-((R)-3-azido-2-(tert-butoxycarbonylamino)-N-(4-((4-methoxy-2,3,6-trimethylphenylsulfonamido)methyl)benzyl)propanamido)succinate 
• 73259-81-1 (R)-2-tert-butoxycarbonyl-3-aminopropionic acid 

Relevant articles and documents

Synthesis and biological evaluation (in Vitro and in Vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αvβ3

A small library of integrin ligand-paclitaxel conjugates 10-13 was synthesized with the aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytotoxic drug. All the paclitaxel-RGD constructs 10-13 inhibited biotinylated vitronectin binding to the purified αVβ3 integrin receptor at low nanomolar concentration and showed in vitro cytotoxic activity against a panel of human tumor cell lines similar to that of paclitaxel. Among the cell lines, the cisplatin-resistant IGROV-1/Pt1 cells expressed high levels of integrin αVβ3, making them attractive to be tested in in vivo models. cyclo[DKP-f3-RGD]-PTX 11 displayed sufficient stability in physiological solution and in both human and murine plasma to be a good candidate for in vivo testing. In tumor-targeting experiments against the IGROV-1/Pt1 human ovarian carcinoma xenotransplanted in nude mice, compound 11 exhibited a superior activity compared with paclitaxel, despite the lower (about half) molar dosage used.

The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: Rational modifications imparting PP1 selectivity

Based on the results from previously reported molecular modeling analyses of the interactions between the inhibitor microcystin and the serine-threonine protein phosphatases 1 and 2A, we have designed analogues of microcystin LA with structural modifications intended to impart PP1 selectivity. The synthesis of several first generation analogues followed by inhibition assays revealed that all three are PP1-selective, as predicted. Although the observed selectivities are modest, one of the designed analogues is more selective for PP1 than any known small molecule inhibitor. Copyright (C) 1999 Elsevier Science Ltd.